These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 25501619)
1. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Solárová Z; Mojžiš J; Solár P Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619 [TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138 [TBL] [Abstract][Full Text] [Related]
3. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives. Kim T; Keum G; Pae AN Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970 [TBL] [Abstract][Full Text] [Related]
4. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Chiosis G; Caldas Lopes E; Solit D Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024 [TBL] [Abstract][Full Text] [Related]
5. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
7. [Heat shock protein 90: novel target for cancer therapy]. Chen Y; Ding J Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726 [TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317 [TBL] [Abstract][Full Text] [Related]
9. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells. Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503 [TBL] [Abstract][Full Text] [Related]
10. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595 [TBL] [Abstract][Full Text] [Related]
11. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Stravopodis DJ; Margaritis LH; Voutsinas GE Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer? Siegelin MD Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257 [TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709 [TBL] [Abstract][Full Text] [Related]
14. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351 [TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: targeting hsp90--who benefits and who does not. Scaltriti M; Dawood S; Cortes J Clin Cancer Res; 2012 Sep; 18(17):4508-13. PubMed ID: 22718860 [TBL] [Abstract][Full Text] [Related]
16. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors. Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839 [TBL] [Abstract][Full Text] [Related]
17. Geldanamycin and its anti-cancer activities. Fukuyo Y; Hunt CR; Horikoshi N Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405 [TBL] [Abstract][Full Text] [Related]
18. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186 [TBL] [Abstract][Full Text] [Related]
19. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects. Garg G; Khandelwal A; Blagg BS Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001 [TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Lu X; Xiao L; Wang L; Ruden DM Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]